Literature DB >> 32212527

Telacebec (Q203), a New Antituberculosis Agent.

Veronique R de Jager1, Rodney Dawson2, Christo van Niekerk3, Jane Hutchings3, Jeongjun Kim3, Naadira Vanker4, Lize van der Merwe5, Jinho Choi3, Kiyean Nam3, Andreas H Diacon6.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32212527     DOI： 10.1056/NEJMc1913327

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  27 in total

1.  Toward a Single-Dose Cure for Buruli Ulcer.

Authors:  Sangeeta S Thomas; Nitin Pal Kalia; Marie-Thérèse Ruf; Gerd Pluschke; Kevin Pethe
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

2.  GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.

Authors:  Eric L Nuermberger; Maria Santos Martínez-Martínez; Olalla Sanz; Beatriz Urones; Jorge Esquivias; Heena Soni; Rokeya Tasneen; Sandeep Tyagi; Si-Yang Li; Paul J Converse; Helena I Boshoff; Gregory T Robertson; Gurdyal S Besra; Katherine A Abrahams; Anna M Upton; Khisimuzi Mdluli; Gary W Boyle; Sam Turner; Nader Fotouhi; Nicholas C Cammack; Juan Miguel Siles; Marta Alonso; Jaime Escribano; Joel Lelievre; Joaquin Rullas-Trincado; Esther Pérez-Herrán; Robert H Bates; Gareth Maher-Edwards; David Barros; Lluís Ballell; Elena Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2022-05-24       Impact factor: 5.938

Review 3.  Targeting the cytochrome bc1 complex for drug development in M. tuberculosis: review.

Authors:  Mushtaq Ahmad Wani; Devendra Kumar Dhaked
Journal:  Mol Divers       Date:  2021-11-11       Impact factor: 3.364

4.  Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model.

Authors:  Deepak V Almeida; Paul J Converse; Till F Omansen; Sandeep Tyagi; Rokeya Tasneen; Jeongjun Kim; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 5.  Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment.

Authors:  Filia Stephanie; Mutiara Saragih; Usman Sumo Friend Tambunan
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

6.  Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis.

Authors:  Catherine Shelton; Matthew McNeil; Renee Allen; Lindsay Flint; Dara Russell; Bryan Berube; Aaron Korkegian; Yulia Ovechkina; Tanya Parish
Journal:  Antimicrob Agents Chemother       Date:  2022-03-09       Impact factor: 5.191

7.  Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects.

Authors:  Soyoung Shin; Beom Soo Shin; Jeongjun Kim; Jinho Choi; Hwankyu Kang; Jiye Ahn; Jane Hutchings; Christo van Niekerk; Dongsik Park; Jaeseung Kim; Yeejin Jeon; Kiyean Nam
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

8.  Identification of Substituted Amino Acid Hydrazides as Novel Anti-Tubercular Agents, Using a Scaffold Hopping Approach.

Authors:  Alistair K Brown; Ahmed K B Aljohani; Fatimah M A Alsalem; Joseph L Broadhead; Jason H Gill; Yucheng Lu; Jonathan D Sellars
Journal:  Molecules       Date:  2020-05-21       Impact factor: 4.411

9.  Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome bc1 Inhibitor and Pretomanid Combination Kills Mycobacterium tuberculosis.

Authors:  Sheng Zeng; Jingran Zhang; Mingwei Sun; Xiaofei Zhang; Gregory M Cook; Tianyu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

10.  Structure guided generation of thieno[3,2-d]pyrimidin-4-amine Mycobacterium tuberculosis bd oxidase inhibitors.

Authors:  Sarah M Hopfner; Bei Shi Lee; Nitin P Kalia; Marvin J Miller; Kevin Pethe; Garrett C Moraski
Journal:  RSC Med Chem       Date:  2021-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.